The Indian scenario offers some unique opportunities for follow on Biologics manufacturing.. There is an  availability of large base of skilled engineering manpower  for designing , and setting up cost –effective world -class manufacturing facilities. There is   a vibrant and global  pharmaceutical manufacturing  Industry which provides a spring-board  for making available a whole range of enabling factors  like quality and regulatory awareness, and  high quality, locally manufactured  pharmaceutical equipment . There is also the   presence of a large number of  personnel qualified in the life sciences and process technologies who can potentially  be trained for the technical demands of the Bio-manufacturing Industry .  Most importantly,  the availability of  product opportunities, and a large  price –sensitive  market  which can absorb these products , provides  a justification to invest in manufacturing facilites as well as a drive to be cost-effective .

This presentation will as an example cover Biocon’s evolution  from an Industrial Enzyme manufacturing company to Asia’s largest recombinant human insulin producer   to currently being a  manufacturer of  novel Monoclonal antibodies.